Urinary biomarkers of oxidative damage in Maple syrup urine disease: The L-carnitine role

International Journal of Developmental Neuroscience

Volumn 42, Issue , 2015, Pages 10-14

  Guerreiro, Gilian ^a   Mescka, Caroline Paula ^a   Sitta, Angela ^b   Donida, Bruna ^a   Marchetti, Desirèe ^b   Hammerschmidt, Tatiane ^a   Faverzani, Jessica ^a   Coelho, Daniella de Moura ^b   Wajner, Moacir ^a,b   Dutra Filho, Carlos Severo ^a   Vargas, Carmen Regla ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Antioxidant; L Carnitine; Maple syrup urine disease; Oxidative stress; Urine

Indexed keywords

2 OXOISOCAPROIC ACID; ANTIOXIDANT; BIOLOGICAL MARKER; CARNITINE; DITYROSINE; ISOPROSTANE DERIVATIVE; UNCLASSIFIED DRUG; 15-F2T-ISOPROSTANE; AMINO ACID; OXOACID; TYROSINE;

AMINO ACID BLOOD LEVEL; ARTICLE; CARNITINE DEFICIENCY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MAPLE SYRUP URINE DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN RESTRICTION; URINALYSIS; ANALYSIS OF VARIANCE; DIET SUPPLEMENTATION; DIET THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; METABOLISM; PRESCHOOL CHILD; TANDEM MASS SPECTROMETRY; URINE;

ACER;

AMINO ACIDS; ANALYSIS OF VARIANCE; ANTIOXIDANTS; BIOMARKERS; CHILD; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ISOPROSTANES; KETO ACIDS; MALE; MAPLE SYRUP URINE DISEASE; TANDEM MASS SPECTROMETRY; TYROSINE;

EID: 84923349171     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2015.02.003     Document Type: Article

References (37)

1. Abdul H.M., Butterfield D.A. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-l-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic. Biol. Med. 2007, 42(3):371-384.
2. Barschak A.G., Sitta A., Deon M., et al. Erythrocyte glutathione peroxidase activity and plasma selenium concentration are reduced in Maple syrup urine disease patients during treatment. Int. J. Dev. Neurosci. 2007, 25:335-338.
3. Barschak A.G., Sitta A., Deon M., et al. Oxidative stress in plasma from Maple syrup urine disease patients during treatment. Metab. Brain Dis. 2008, 23:71-80.
4. Barschak A.G., Sitta A., Deon M., et al. Evidence that oxidative stress is increased in plasma from patients with Maple syrup urine disease. Metab. Brain Dis. 2006, 21:279-286.
5. Borglund M., Sjoblad S., Akesson B. Effect of selenium supplementation on the distribution of selenium among plasma proteins of a patient with Maple syrup urine disease. Eur. J. Pediatr. 1989, 148(8):767-769.
6. Bridi R., Braum C.A., Zorzi G.K., et al. Alpha-keto acids accumulating in Maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats. Metab. Brain Dis. 2005, 20:155-167.
7. Bridi R., Fontella F.U., Pulronik V., et al. A chemically-induced acute model of Maple syrup urine disease in rats for neurochemical studies. J. Neurosci. Methods 2006, 155:224-230.
8. Bykov I.L. Effect of l-carnitine on metabolic disorders in rats with experimental acyl-CoA dehydrogenase deficiency. Eksp Klin Farmakol. 2004, 67(6):48-52.
9. Chace D.H., Hillman S.L., Van Hove J.L., Naylor E.W. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin. Chem. 1997, 43:2106-2113.
10. Chalmers R.A., Roe C.R., Stacey T.E., Hoppel C.L. Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr. Res. 1984, 18(12):1325-1328.
11. Chuang D.T., Shih V.E. Maple syrup urine disease (branched-chain ketoaciduria). The Metabolic and Molecular Bases of Inherited Disease 2011, 1971-2005. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudt, W.L. Sly, D. Valle (Eds.).
12. Coitinho A.S., de Mello C.F., Lima T.T., de Bastiani J., Fighera M.R., Wajner M. Pharmacological evidence that alpha-ketoisovaleric acid induces convulsions through GABAergic and glutamatergic mechanisms in rats. Brain Res. 2001, 89:68-73.
13. Colome C., Sierra C., Vilaseca M.A. Congenital errors of metabolism: cause of oxidative stress?. Med. Clin. 2000, 115:111-117.
14. Gulcin I. Antioxidant and antiradical activities of l-carnitine. Life Sci. 2006, 78:803-811.
15. Halliwell B., Gutteridge M.C. Free Radicals in Biology and Medicine 2007, Oxford University Press Inc., New York. fourth ed.
16. Harris R.A., Joshi M., Jeoung N.H. Mechanisms responsible for regulation of branched-chain amino acid catabolism. Biochem. Biophys. Res. Commun. 2004, 313:391-396.
17. Hoffmann G.F. Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency. Neuropediatrics 1996, 27:115-123.
18. Joseph M.H., Marsden C.A. Amino acids and small peptides. HPLC of Small Peptides 1986, 13-27. Oxford. C.F. Lim (Ed.).
19. Jouvet P., Rustin P., Taylor D.L. Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: implications for neurological impairment associated with Maple syrup urine disease. Mol. Biol. Cell 2000, 11:1919-1932.
20. Kirschbaum B. Correlative studies of urine fluorescence and free radical indicators. Clin. Nephrol. 2002, 58:344-349.
21. Kölker S. Diagnosis and management of glutaric aciduria type I - revised recommendations. J. Inherit. Metab. Dis. 2011, 34:677-694.
22. Mescka C., Moraes T., Rosa A., et al. In vivo neuroprotective effect of l-carnitine against oxidative stress in Maple syrup urine disease. Meta. Brain Dis. 2011, 26:21-28.
23. Mescka C.P., Wayhs C.A., Vanzin C.S. Protein and lipid damage in Maple syrup urine disease patients: l-carnitine effect. Int. J. Dev. Neurosci. 2013, 31:21-24.
24. Miguel-Carrasco J.L., Monserrat M.T., Mate A., Vázquez C.M. Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur. J. Pharmacol. 2010, 632:65-72.
25. Ribas G.S., Biancini G.B., Mescka C.P., et al. Oxidative stress parameters in urine from patients with disorders of propionate metabolism: a beneficial effect of l-carnitine supplementation. Cell. Mol. Neurobiol. 2012, 32:77-82.
26. Ribas G.S., Manfredini V., De Mari J.F. Reduction of lipid and protein damage in patients with disorders of propionate metabolism under treatment: a possible protective role of l-carnitine supplementation. Int. J. Dev. Neurosci. 2010, 28:127-132.
27. Ribas G.S., Sitta A., Wajner M., Vargas C.R. Oxidative stress in phenylketonuria: what is the evidence?. Cell. Mol. Neurobiol. 2011, 31:653-662.
28. Ribas G.S., Vargas C.R., Wajner M. l-Carnitine supplementation as a potencial antioxidant therapy for inherited neurometabolic diseases. Gene 2014, 533:469-476.
29. Sgaravatti A.M., Rosa R.B., Schuck P.F., et al. Inhibition of brain energy metabolism by the alpha-keto acids accumulating in Maple syrup urine disease. Biochim. Biophys. Acta 2003, 1639:232-238.
30. Sitta A., Ribas G.S., Mescka C.P., Barschak A.G., Wajner M., Vargas C.R. Neurological damage in MSUD: the role of oxidative stress. Cell. Mol. Neurobiol. 2014, 34:157-165.
31. Sitta A., Vanzin C.S., Vargas C.R. Evidence that l-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients. Cell. Mol. Neurobiol. 2011, 31:429-436.
32. Sweetmann L. Organic acid analysis. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual 1995, Wiley-Liss, New York. F.A. Hommes (Ed.).
33. Tavares R.G., Santos C.E., Tasca C.I., Wajner M., Souza D.O., Dutra-Filho C.S. Inhibition of glutamate uptake into synaptic vesicles of rat brain by the metabolites accumulating in Maple syrup urine disease. J. Neurol. Sci. 2000, 181:44-49.
34. Treacy E., Clow C.L., Reade T.R., Chitayat D., Mamer O.A., Scriver C.R. Maple syrup urine disease: interrelationship between branched-chainamino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination. J. Inherit. Metab. Dis. 1992, 15:121-135.
35. Wajner M., Latini A., Wyse A.T., Dutra-Filho C.S. The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J. Inher. Metab. Dis. 2004, 27:427-448.
36. Wendel U., Ogier de Baulny H. Branched-chain organic acidurias/acidemias. Inborn Metabolic Diseases 2006, 245-262. Springer, Heidelberg. fourth ed. J. Fernandes, J.-M. Saudubray, G. van den Berghe, J.H. Walter (Eds.).
37. Zielke H.R., Huang Y., Baab P., Collins R.M.J., Zielke C.L., Tildon J.T. Effect of alpha-ketoisocaproate and leucine on the in vivo oxidation of glutamate and glutamine in the rat brain. Neurochem. Res. 1997, 22:1159-1164.